Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)

Clinical Cancer Research

Volumn 8, Issue 10, 2002, Pages 3250-3258

  Bianco, Cataldo ^a   Tortora, Giampaolo ^a   Bianco, Roberto ^a   Caputo, Roberta ^a   Veneziani, Bianca Maria ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Troiani, Teresa ^a   Fontanini, Gabriella ^b   Raben, David ^c   Pepe, Stefano ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0036795061     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19: 183-232, 1995.
2. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 82: 241-250, 1999.
3. Wosikowski, K., Schuurhuis, D., Kops, G. J. P. L., Saceda, M., and Bates, S. E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res., 2: 2405-2414, 1997.
4. Akimoto, T., Hunter, N. R., Buchmiller, L., Mason, K. A., Ang, K. K., and Milas, L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res., 5: 2884-2890, 1999.
5. Harari, P. M., and Huang, S-M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin. Radiat. Oncol., 11: 281-289, 2001.
6. Schmidt-Ullrich, R. K., Mikkelsen, R. B., Dent, P., Todd, D. G., Valerie, K., Kavanagh, B. D., Contessa, J. N., Rorrer, W. K., and Chen, P. B. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene, 15: 1191-1197, 1997.
7. Dent, P., Reardon, D. B., Park, J. S., Bowers, G., Logsdon, C., Valerie, K., and Schmidt-Ullrich. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell., 10: 2493-2506, 1999.
8. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
9. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
10. Ciardiello, F., Caputo, R., Bianco, R., Damianco, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
11. Sirotnak, F. M., Zakowsky, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
12. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.
13. Ciardiello, F., Caputo, R., Borriello, G., Del Bufalo, D., Biroccio, A., Zupi, G., Bianco, A. R., and Tortora, G. ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int. J. Cancer, 98: 463-469, 2002.
14. Huang, S-M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
15. Huang, S-M., and Harari, P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res., 6: 2166-2174, 2000.
16. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, and J. Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res., 6: 701-708, 2000.
17. Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A. R., and Ciardiello, F. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin. Cancer Res., 6: 4343-4350, 2000.
18. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and antiepidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 909-916, 1999.
19. Ciardiello, F., Damiano, V., Bianco, C., di Isemia, G., Ruggiero, A., Caraglia, M., Tagliaferri, P., Baselga, J., Mendelsohn, J., Bianco, A. R., and Tortora, G. Cooperative antiproliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin. Cancer Res., 1: 161-167, 1995.
20. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. (Bethesda), 89: 341-343, 1997.
21. Harari, P. M., and Huang, S-M. Modulation of molecular targets to enhance radiation. Clin. Cancer Res., 6: 323-325, 2000.
22. Ryan, P. D., and Chabner, B. A. On receptor inhibitors and chemotherapy. Clin. Cancer Res., 6: 4607-4609, 2000.
23. Sheridan, M. T., O'Dweyer, T., Seymour, C. B., and Mothersill, C. E. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig., 5: 180-186, 1997.
24. Lammering, G., Hewit, T. H., Hawkins, W. T., Contessa, J. N., Reardon, D. B., Lin, P-S., Valerie, K., Dent, P., Mikkelsen, R. B., Schmidt-Ullrich, R. K. Epidermal growth factor receptor as genetic therapy for carcinoma cell radiosensitization. J. Natl. Cancer Inst. (Bethesda), 93: 921-929, 2001.
25. Raben, D., Helfrich, B. A., Chan, D., Johnson, G., Bunn, P. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin. Oncology 29: 37-46, 2002.
26. Williams, K., Telfer, B. A., Stratford, I. J., and Wedge, S. R. ZD1839 (Iressa), a specific oral epidermal growth factor receptortyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer, 86: 1157-1161, 2002.
27. Huang, S., Li, J., and Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Proceed. 12th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, Abs. 259, Miami Beach, FL. October 29-November 2, 2001.
28. Baselga, J., Yano, S., Giaccone, G., Nakagawa, K., Tamura, T., Douillard, J., Nishiwaki, Y., Vansteenkiste, J. F., Kudou, S., Rischin, D., Eek, R. W., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R., and Fukuoka, M. Initial results from a Phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced nonsmall-cell lung cancer (IDEAL 1). Proceed. 12th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, Abs. 630A, Miami Beach, FL. October 29-November 2, 2001.
29. Miller, V. A., Johnson, D., Heelan, R. T., Pizzo, B. A., Perez, W. J., Bass, A., Kris, M. G., Ochs, J., and Averbuch, S. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC). Proc. Am. Soc. Clin. Oncol., 21: A1301, 2001.
30. Hammond, L. A., Figueroa, J., Schwartzberg, L., Ochoa, L., Hidalgo, M., Olivo, N., Schwartz, G., Smith, L., Ochs, J., and Rowinsky, E. K. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin in patients with advanced colorectal cancer (aCRC). Proc. Am. Soc. Clin. Oncol., 21: A544, 2001.
31. Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., Cooper, M. R., and Waksal, H. W. Phase I study of anti-epidermal growth factor antibody Cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol., 19: 3234-3243, 2001.